Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD features prominently at AAIC Conference in London
AMYPAD features prominently at AAIC Conference in London 21 Jul 2017 The AAIC conference was a great opportunity for presenting AMYPAD since the project featured prominently in a number of key communications......
Geneva Roadmap paper mentions AMYPAD
Geneva Roadmap paper mentions AMYPAD 12 Jul 2017 An article has mentioned AMYPAD as a research initiative addressing amyloid imaging....
AMYPAD publishes its flyer
AMYPAD publishes its flyer 07 Jun 2017 The AMYPAD consortium releases a flyer presenting its project. It includes general information on Alzheimer's disease and ß-amyloid...
"At this moment, there is a massive effort to better understand the natural history of Alzheimer’s Disease (AD), as well to improve its management. These efforts wish to increase the chances of success for future clinical trials by allowing them to target populations at the early stages of the disease, when the damage could still be reversed. AMYPAD comes to provide valuable insight on a fundamental piece of the AD puzzle: the accumulation of β-amyloid plaques. We will be doing so by determining the role and value of amyloid imaging in disease diagnosis, prognosis, and potential for treatment monitoring - which will be a crucial step forward in the global fight against AD.” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.